Articles

Search Articles

Advanced search
Help

Catalogue

Articles

Databases

X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (5402) 5402
Publication (338) 338
Newsletter (131) 131
Book Review (57) 57
Magazine Article (39) 39
Newspaper Article (12) 12
Dissertation (9) 9
Book Chapter (6) 6
Trade Publication Article (6) 6
Conference Proceeding (3) 3
Book / eBook (2) 2
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (3481) 3481
salmeterol (3480) 3480
male (1958) 1958
albuterol - analogs & derivatives (1931) 1931
asthma (1904) 1904
salmeterol xinafoate (1891) 1891
respiratory system (1875) 1875
female (1853) 1853
asthma - drug therapy (1671) 1671
index medicus (1617) 1617
administration, inhalation (1462) 1462
middle aged (1382) 1382
adult (1295) 1295
fluticasone (1110) 1110
bronchodilator agents - therapeutic use (1102) 1102
albuterol - therapeutic use (1083) 1083
pulmonary disease, chronic obstructive - drug therapy (1051) 1051
aged (1039) 1039
bronchodilator agents - administration & dosage (987) 987
albuterol - administration & dosage (915) 915
double-blind method (900) 900
formoterol (886) 886
treatment outcome (885) 885
drug therapy, combination (842) 842
obstructive pulmonary-disease (842) 842
pharmacology & pharmacy (841) 841
copd (766) 766
fluticasone propionate (700) 700
drug therapy (695) 695
chronic obstructive pulmonary disease (689) 689
adolescent (651) 651
adrenergic beta-agonists - therapeutic use (651) 651
medicine, general & internal (635) 635
inhaled corticosteroids (598) 598
formoterol fumarate (589) 589
lung diseases, obstructive (589) 589
exacerbations (580) 580
drug combinations (567) 567
salbutamol (551) 551
corticosteroids (544) 544
tiotropium (536) 536
allergy (526) 526
budesonide (509) 509
asthma - physiopathology (502) 502
androstadienes - administration & dosage (491) 491
adrenergic beta-agonists - administration & dosage (488) 488
child (483) 483
pulmonary disease, chronic obstructive - physiopathology (465) 465
bronchodilator agents - adverse effects (436) 436
androstadienes - therapeutic use (435) 435
albuterol - pharmacology (434) 434
immunology (413) 413
adrenal cortex hormones - administration & dosage (400) 400
dose-response relationship, drug (394) 394
forced expiratory volume - drug effects (389) 389
efficacy (383) 383
albuterol - adverse effects (373) 373
therapy (373) 373
anti-asthmatic agents - therapeutic use (372) 372
cross-over studies (372) 372
quality of life (372) 372
double-blind (363) 363
research (360) 360
care and treatment (357) 357
forced expiratory volume (354) 354
ethanolamines - administration & dosage (346) 346
cardiac & cardiovascular systems (336) 336
time factors (336) 336
anti-asthmatic agents - administration & dosage (331) 331
albuterol (320) 320
dosage and administration (320) 320
tiotropium bromide (319) 319
adrenal cortex hormones - therapeutic use (316) 316
ethanolamines - therapeutic use (307) 307
adrenergic beta-agonists - pharmacology (305) 305
respiratory function tests (304) 304
safety (304) 304
animals (301) 301
severity of illness index (296) 296
randomized controlled trials as topic (295) 295
lung-function (294) 294
mortality (291) 291
children (286) 286
analysis (284) 284
drug administration schedule (277) 277
respiratory tract diseases (277) 277
inflammation (272) 272
fluticasone-salmeterol drug combination (270) 270
adrenergic beta-agonists - adverse effects (268) 268
aged, 80 and over (263) 263
pulmonary and respiratory medicine (263) 263
salmeterol/fluticasone propionate (261) 261
bronchodilator agents - pharmacology (258) 258
nebulizers and vaporizers (256) 256
pulmonary/respiratory (251) 251
persistent asthma (243) 243
risk factors (231) 231
combination (226) 226
antiasthmatic agents (223) 223
abridged index medicus (222) 222
more...
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (5215) 5215
German (109) 109
French (86) 86
Spanish (45) 45
Japanese (27) 27
Polish (27) 27
Italian (25) 25
Chinese (23) 23
Portuguese (11) 11
Danish (9) 9
Russian (8) 8
Romanian (4) 4
Dutch (3) 3
Czech (2) 2
Korean (2) 2
Norwegian (2) 2
Swedish (2) 2
Turkish (2) 2
Hebrew (1) 1
Hungarian (1) 1
Slovak (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


1. Full Text Salmeterol, a β2 Adrenergic Agonist, Promotes Adult Hippocampal Neurogenesis in a Region-Specific Manner
by Bondi, Heather and Cuccurazzu, Bruna and Grilli, Mariagrazia and Bortolotto, Valeria and Canonico, Pier Luigi and Rinaldi, Maurizio
Frontiers in Pharmacology, ISSN 1663-9812, 09/2019
Salmeterol
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
2. Full Text Single inhaler triple therapy versus inhaled corticosteroid plus long-acting beta(2)-agonist therapy for chronic obstructive pulmonary disease (TRILOGY): a double-blind, parallel group, randomised controlled trial
by Singh, D and Papi, A and Corradi, M and Pavlisova, I and Montagna, I and Francisco, C and Cohuet, G and Vezzoli, S and Scuri, M and Vestbo, J
LANCET, ISSN 0140-6736, 09/2016, Volume 388, Issue 10048, pp. 963 - 973
Background Few data are available for the efficacy of "triple therapy" with two long-acting bronchodilators and an inhaled corticosteroid in chronic... 
POPULATION | MEDICINE, GENERAL & INTERNAL | LUNG-FUNCTION | EXACERBATIONS | INDIVIDUAL COMPONENTS | TIOTROPIUM | FLUTICASONE PROPIONATE/SALMETEROL | GLYCOPYRRONIUM | COPD | SALMETEROL | SALMETEROL/FLUTICASONE
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
3. ANÁLISIS DE COSTO EFECTIVIDAD DEL USO DE BUDESONIDA/FORMOTEROL FRENTE A SALMETEROL/FLUTICASONA, EN PACIENTES CON ASMA MODERADA Y SEVERA EN COLOMBIA
by ME Romero Prada and NC Roa Cardenas and LM Huerfano
Value in Health : The Journal of the International Society for Pharmacoeconomics and Outcomes Research, ISSN 1098-3015, 10/2017, Volume 20, Issue 9, p. A889
Salmeterol | Formoterol
Journal Article
Details down arrow
4. Full Text Indacaterol–Glycopyrronium versus Salmeterol–Fluticasone for COPD
by Wedzicha, Jadwiga A and Banerji, Donald and Chapman, Kenneth R and Vestbo, Jørgen and Roche, Nicolas and Ayers, R. Timothy and Thach, Chau and Fogel, Robert and Patalano, Francesco and Vogelmeier, Claus F and FLAME Investigators
The New England Journal of Medicine, ISSN 0028-4793, 06/2016, Volume 374, Issue 23, pp. 2222 - 2234
This randomized trial compared a long-acting beta-agonist (LABA) plus a glucocorticoid with a LABA plus a long-acting muscarinic antagonist for preventing... 
MEDICINE, GENERAL & INTERNAL | OBSTRUCTIVE PULMONARY-DISEASE | EFFICACY | TO-SEVERE COPD | BLOOD EOSINOPHILS | SAFETY | PARALLEL-GROUP | INHALED CORTICOSTEROIDS | LUNG-FUNCTION | DOUBLE-BLIND | EXACERBATIONS | Glycopyrrolate - adverse effects | Indans - adverse effects | Pulmonary Disease, Chronic Obstructive - mortality | Glucocorticoids - therapeutic use | Double-Blind Method | Glycopyrrolate - therapeutic use | Humans | Middle Aged | Administration, Inhalation | Male | Fluticasone-Salmeterol Drug Combination - therapeutic use | Muscarinic Antagonists - therapeutic use | Indans - therapeutic use | Fluticasone-Salmeterol Drug Combination - adverse effects | Quinolones - adverse effects | Quinolones - therapeutic use | Adrenergic beta-2 Receptor Agonists - therapeutic use | Female | Aged | Drug Combinations | Pulmonary Disease, Chronic Obstructive - drug therapy | Lung diseases, Obstructive | Care and treatment | Indacaterol | Dosage and administration | Salmeterol | Respiratory therapy | Acetylcholine receptors (muscarinic) | Glucocorticoids | Lung diseases | Fluticasone | Preventive medicine | Patients | Inhalation | Obstructive lung disease | Comparative studies | Chronic obstructive pulmonary disease | Pharmaceuticals | Life Sciences | Human health and pathology
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
5. Full Text Inhaled corticosteroids in COPD and the risk of serious pneumonia
by Suissa, Samy and Patenaude, Valérie and Lapi, Francesco and Ernst, Pierre
Thorax, ISSN 0040-6376, 11/2013, Volume 68, Issue 11, pp. 1029 - 1036
Background Inhaled corticosteroids (ICS) are known to increase the risk of pneumonia in patients with chronic obstructive pulmonary disease (COPD). It is... 
RHEUMATOID-ARTHRITIS | OBSTRUCTIVE PULMONARY-DISEASE | LONG-TERM USE | METAANALYSIS | PHARMACOKINETICS | RESPIRATORY SYSTEM | FLUTICASONE PROPIONATE/SALMETEROL 250/50 | SALMETEROL/FLUTICASONE PROPIONATE | EXACERBATIONS | SALMETEROL | HOSPITALIZATION | Glucocorticoids - administration & dosage | Quebec - epidemiology | Follow-Up Studies | Pneumonia - epidemiology | Humans | Middle Aged | Risk Factors | Administration, Inhalation | Male | Incidence | Dose-Response Relationship, Drug | Time Factors | Pneumonia - chemically induced | Female | Aged | Retrospective Studies | Glucocorticoids - adverse effects | Pulmonary Disease, Chronic Obstructive - drug therapy | Lung diseases, Obstructive | Pneumonia | Corticosteroids | Bacterial pneumonia | Dosage and administration | Drug therapy | Risk factors | 1506 | Epidemiology
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
6. Full Text INDACATEROL/GLYCOPYRRONIUM (IND/GLY) REDUCES THE RISK OF CLINICALLY IMPORTANT DETERIORATION (CID) VERSUS SALMETEROL/FLUTICASONE (SFC): THE FLAME STUDY
Respirology, ISSN 1323-7799, 11/2017, Volume 22, Issue S3, pp. 178 - 178
Salmeterol | Fluticasone
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
7. Full Text IMPROVEMENT IN SGRQ COMPONENT SCORE WITH INDACATEROL/ GLYCOPYRRONIUM VERSUS SALMETEROL/FLUTICASONE: RESULTS FROM THE FLAME STUDY
Respirology, ISSN 1323-7799, 11/2017, Volume 22, Issue S3, pp. 176 - 177
Salmeterol | Fluticasone
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
8. Full Text Combined corticosteroid and long-acting beta(2)-agonist in one inhaler versus long-acting beta(2)-agonists for chronic obstructive pulmonary disease
by Nannini, Luis Javier and Nannini, Luis Javier and Lasserson, Toby J and Lasserson, Toby J and Poole, Phillippa and Poole, Phillippa
Cochrane database of systematic reviews (Online), ISSN 1469-493X, 2012, Volume 2012, Issue 9, p. CD006829
Background Both inhaled steroids (ICS) and long-acting beta(2)-agonists (LABA) are used in the management of chronic obstructive pulmonary disease (COPD). This... 
Adrenal Cortex Hormones [administration & dosage; adverse effects] | COST-EFFECTIVENESS | Adrenergic beta-Agonists [administration & dosage; adverse effects] | CLINICAL-TRIAL | Humans | FLUTICASONE PROPIONATE/SALMETEROL 250/50 | SALMETEROL/FLUTICASONE PROPIONATE | COPD EXACERBATIONS | LUNG-FUNCTION | RANDOMIZED CONTROLLED-TRIAL | Pneumonia [chemically induced] | Randomized Controlled Trials as Topic | SALMETEROL | Bronchodilator Agents [administration & dosage; adverse effects] | Pulmonary Disease, Chronic Obstructive [drug therapy; mortality] | MEDICINE, GENERAL & INTERNAL | METERED-DOSE INHALER | Quality of Life | Adult | Drug Therapy, Combination | 50 MU-G | Drug Combinations | Nebulizers and Vaporizers | Pulmonary Disease, Chronic Obstructive - mortality | Ethanolamines - adverse effects | Formoterol Fumarate | Bronchodilator Agents - administration & dosage | Fluticasone | Ethanolamines - administration & dosage | Pneumonia - chemically induced | Adrenergic beta-Agonists - administration & dosage | Albuterol - administration & dosage | Bronchodilator Agents - adverse effects | Adrenergic beta-Agonists - adverse effects | Salmeterol Xinafoate | Albuterol - analogs & derivatives | Adrenal Cortex Hormones - adverse effects | Drug Therapy, Combination - methods | Androstadienes - administration & dosage | Budesonide - adverse effects | Budesonide - administration & dosage | Androstadienes - adverse effects | Albuterol - adverse effects | Adrenal Cortex Hormones - administration & dosage | Pulmonary Disease, Chronic Obstructive - drug therapy
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
9. Full Text Utility of Von Pechman synthesis of coumarin reaction for development of spectrofluorimetric method for quantitation of salmeterol xinafoate in pharmaceutical preparations and human plasma
by Awad, Mohamed and Hammad, Mohamed A and Abdel‐Megied, Ahmed M and Omar, Mahmoud A
Luminescence, ISSN 1522-7235, 08/2018, Volume 33, Issue 5, pp. 913 - 918
Simple, precise and selective spectrofluorimetric technique was evolved for quantitation of selective β2 agonist drug namely salmeterol xinafoate (SAL).... 
coumarin derivatives | spectrofluorimetry, salmeterol xinafoate | human plasma | pharmaceutical analysis | spectrofluorimetry | BIOCHEMISTRY & MOLECULAR BIOLOGY | salmeterol xinafoate | DRY-POWDER INHALERS | Fluorescent Dyes - chemical synthesis | Fluorescent Dyes - chemistry | Spectrometry, Fluorescence - methods | Limit of Detection | Reproducibility of Results | Temperature | Solvents - chemistry | Humans | Coumarins - chemistry | Sulfuric Acids - chemistry | Salmeterol Xinafoate - analysis | Time Factors | Salmeterol Xinafoate - blood | Salmeterol Xinafoate - chemistry | Pharmaceutical Preparations | Acetoacetates - chemistry | Analysis | Methods | Salmeterol | Drugs | Correlation coefficient | Analytical methods | Regulatory agencies | Methodology | Correlation coefficients | Fluorescence | Firmness | Quantitation | Phenolic compounds | Coumarin | Recovery | Blood plasma | Salmeterol xinafoate | Mathematical analysis | Phenols | Detection | Chemical synthesis | Pharmaceuticals
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
10. Full Text LANTERN: A randomized study of QVA149 versus salmeterol/fluticasone combination in patients with COPD
by Zhong, Nanshan and Wang, Changzheng and Zhou, Xiangdong and Zhang, Nuofu and Humphries, Michael and Wang, Linda and Thach, Chau and Patalano, Francesco and Banerji, Donald and LANTERN Investigators
International Journal of COPD, ISSN 1176-9106, 06/2015, Volume 10, pp. 1015 - 1026
Background: The current Global initiative for chronic Obstructive Lung Disease (GOLD) treatment strategy recommends the use of one or more bronchodilators... 
Clinical trial | agonists | Long-acting muscarinic antagonist | Long-acting β | COPD | clinical trial | COST-EFFECTIVENESS | SAFETY | INHALED CORTICOSTEROIDS | SALMETEROL | FORMOTEROL | OBSTRUCTIVE PULMONARY-DISEASE | PRIMARY-CARE | FLUTICASONE PROPIONATE | RESPIRATORY SYSTEM | DOUBLE-BLIND | TIOTROPIUM | long-acting beta-agonists | long-acting muscarinic antagonist | Bronchodilator Agents - therapeutic use | Indans - adverse effects | Spirometry | Glucocorticoids - administration & dosage | Glucocorticoids - therapeutic use | Bronchodilator Agents - administration & dosage | Humans | Middle Aged | Muscarinic Antagonists - adverse effects | Male | Fluticasone-Salmeterol Drug Combination - therapeutic use | Pulmonary Disease, Chronic Obstructive - physiopathology | Muscarinic Antagonists - therapeutic use | Indans - therapeutic use | Recovery of Function | Fluticasone-Salmeterol Drug Combination - adverse effects | Forced Expiratory Volume | Quinolones - adverse effects | Time Factors | Adrenergic beta-2 Receptor Agonists - adverse effects | Quinolones - therapeutic use | Adrenergic beta-2 Receptor Agonists - therapeutic use | Adult | Female | Surveys and Questionnaires | Indans - administration & dosage | Bronchodilator Agents - adverse effects | Glucocorticoids - adverse effects | Glycopyrrolate - adverse effects | Severity of Illness Index | Pulmonary Disease, Chronic Obstructive - diagnosis | Double-Blind Method | Glycopyrrolate - therapeutic use | Administration, Inhalation | Treatment Outcome | Lung - physiopathology | Glycopyrrolate - analogs & derivatives | Fluticasone-Salmeterol Drug Combination - administration & dosage | Muscarinic Antagonists - administration & dosage | Quinolones - administration & dosage | Glycopyrrolate - administration & dosage | Lung - drug effects | Adrenergic beta-2 Receptor Agonists - administration & dosage | Aged | Nebulizers and Vaporizers | Pulmonary Disease, Chronic Obstructive - drug therapy | Lung diseases, Obstructive | Drug therapy, Combination | Comparative analysis | Drug therapy | Methods | Bronchodilator agents
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
11. Full Text Population pharmacokinetics of fluticasone propionate/salmeterol using two different dry powder inhalers
by Soulele, K and Macheras, P and Silvestro, L and Rizea Savu, S and Karalis, V
European Journal of Pharmaceutical Sciences, ISSN 0928-0987, 12/2015, Volume 80, pp. 33 - 42
The combination of fluticasone propionate (FLP) and salmeterol (SAL) is often used in clinical practice for the treatment of pulmonary disorders. The purpose... 
Population pharmacokinetics | Dry powder inhalers | Non-linear mixed effect modeling | Salmeterol | Fluticasone propionate | SALMETEROL/FLUTICASONE PROPIONATE | HEALTHY | MODEL | SIMULATION | PLASMA | FORMULATIONS | PHARMACOLOGY & PHARMACY | BIOEQUIVALENCE | CORTICOSTEROIDS | PHARMACODYNAMIC EVALUATION | Bronchodilator Agents - blood | Fluticasone-Salmeterol Drug Combination - pharmacokinetics | Bronchodilator Agents - administration & dosage | Humans | Middle Aged | Male | Fluticasone-Salmeterol Drug Combination - administration & dosage | Cross-Over Studies | Young Adult | Bronchodilator Agents - pharmacokinetics | Adolescent | Adult | Female | Fluticasone-Salmeterol Drug Combination - blood | Dry Powder Inhalers - methods | Therapeutic Equivalency | Powders | Corticosteroids | Inhalers | Analysis
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
12. Full Text Glycopyrronium once-daily significantly improves lung function and health status when combined with salmeterol/fluticasone in patients with COPD: the GLISTEN studya randomised controlled trial
by Frith, PA and Thompson, PJ and Ratnavadivel, R and Chang, CL and Bremner, P and Day, P and Frenzel, C and Kurstjens, N and Glisten Study Grp
THORAX, ISSN 0040-6376, 06/2015, Volume 70, Issue 6, pp. 519 - 527
Background The optimal use of various therapeutic combinations for moderate/severe chronic obstructive pulmonary disease (COPD) is unclear. The GLISTEN trial... 
PROPIONATE | INDACATEROL | MODERATE | FORMOTEROL | OBSTRUCTIVE PULMONARY-DISEASE | EFFICACY | RESPIRATORY SYSTEM | COPD Pharmacology | TIOTROPIUM | FLUTICASONE PROPIONATE/SALMETEROL | COMBINATION | SALMETEROL
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
13. Full Text Blood eosinophils and response to maintenance chronic obstructive pulmonary disease treatment data from the FLAME Trial
by Roche, Nicolas and Chapman, Kenneth R and Vogelmeier, Claus F and Herth, Felix J.F and Thach, Chau and Fogel, Robert and Olsson, Petter and Patalano, Francesco and Banerji, Donald and Wedzicha, Jadwiga A
American Journal of Respiratory and Critical Care Medicine, ISSN 1073-449X, 05/2017, Volume 195, Issue 9, pp. 1189 - 1197
Rationale: Post hoc analyses suggest that blood eosinophils have potential as a predictive biomarker of inhaled corticosteroid efficacy in the management of... 
Bronchodilation | QVA149 | Exacerbations | Chronic obstructive pulmonary disease | Inhaled corticosteroids | PNEUMONIA RISK | EFFICACY | DAILY ACLIDINIUM BROMIDE | SALMETEROL/FLUTICASONE PROPIONATE | SALMETEROL-FLUTICASONE | RESPIRATORY SYSTEM | exacerbations | PARALLEL-GROUP | DOUBLE-BLIND | COPD PATIENTS | bronchodilation | chronic obstructive pulmonary disease | inhaled corticosteroids | CRITICAL CARE MEDICINE | Double-Blind Method | Eosinophils - drug effects | Humans | Middle Aged | Male | Treatment Outcome | Fluticasone-Salmeterol Drug Combination - therapeutic use | Biomarkers - blood | Adrenal Cortex Hormones - therapeutic use | Indans - therapeutic use | Quinolones - therapeutic use | Pulmonary Disease, Chronic Obstructive - blood | Adrenergic beta-2 Receptor Agonists - therapeutic use | Adrenergic beta-2 Receptor Agonists - administration & dosage | Female | Aged | Leukocyte Count | Drug Therapy, Combination | Adrenal Cortex Hormones - administration & dosage | Pulmonary Disease, Chronic Obstructive - drug therapy | Respiratory therapy | Disease prevention | Studies | Pneumonia | Antibiotics | Critical care | Pharmaceutical industry | Asthma
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
14. Full Text Combination inhaled steroid and long-acting beta2-agonist versus tiotropium for chronic obstructive pulmonary disease
by Welsh, Emma J and Welsh, Emma J and Cates, Christopher J and Cates, Christopher J and Poole, Phillippa and Poole, Phillippa
The Cochrane database of systematic reviews, ISSN 1469-493X, 2013, Volume 5, Issue 5, p. CD007891
Background Combination therapy (inhaled corticosteroids and long-acting beta2-agonists) and tiotropium are both used in the treatment of chronic obstructive... 
MODERATE | Adrenergic beta-Agonists [administration & dosage] | Patient Dropouts [statistics & numerical data] | Humans | SALMETEROL/FLUTICASONE PROPIONATE | Administration, Inhalation | BUDESONIDE/FORMOTEROL | FLUTICASONE PROPIONATE/SALMETEROL | PNEUMONIA | Pneumonia [drug therapy] | SALMETEROL | Pulmonary Disease, Chronic Obstructive [drug therapy; mortality] | MEDICINE, GENERAL & INTERNAL | Drug Therapy, Combination [methods] | Scopolamine Derivatives [administration & dosage] | Albuterol [administration & dosage; analogs & derivatives] | TRIPLE THERAPY | PLUS FLUTICASONE | BROMIDE | Androstadienes [administration & dosage]; Bronchodilator Agents [administration & dosage] | COPD | Pulmonary Disease, Chronic Obstructive - mortality | Patient Dropouts - statistics & numerical data | Salmeterol Xinafoate | Bronchodilator Agents - administration & dosage | Albuterol - analogs & derivatives | Fluticasone | Drug Therapy, Combination - methods | Androstadienes - administration & dosage | Pneumonia - drug therapy | Albuterol - administration & dosage | Scopolamine Derivatives - administration & dosage | Adrenergic beta-2 Receptor Agonists - administration & dosage | Pulmonary Disease, Chronic Obstructive - drug therapy | Tiotropium Bromide
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
15. Full Text Arginine-16 β2 adrenoceptor genotype predisposes to exacerbations in young asthmatics taking regular salmeterol
by Palmer, C N A and Lipworth, B J and Lee, S and Ismail, T and Macgregor, D F and Mukhopadhyay, S
Thorax, ISSN 0040-6376, 11/2006, Volume 61, Issue 11, pp. 940 - 944
Background: The homozygous presence of the arginine-16 variant of the β2 adrenoceptor gene ADRB2 reverses the benefits from the regular use of short acting β2... 
polymorphism | ADRB2 | children | salmeterol | Asthma
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
16. Full Text Once-daily inhaled fluticasone furoate and vilanterol versus vilanterol only for prevention of exacerbations of COPD: two replicate double-blind, parallel-group, randomised controlled trials
by Dransfield, Mark T, MD and Bourbeau, Jean, MD and Jones, Paul W, Prof and Hanania, Nicola A, MD and Mahler, Donald A, Prof and Vestbo, Jørgen, Prof and Wachtel, Andrew, MD and Martinez, Fernando J, MD and Barnhart, Frank, DVM and Sanford, Lisa, MSc and Lettis, Sally, PhD and Crim, Courtney, MD and Calverley, Peter MA, Prof
Lancet Respiratory Medicine, The, ISSN 2213-2600, 2013, Volume 1, Issue 3, pp. 210 - 223
Summary Background Whether the combination of a once-daily inhaled corticosteroid with a once-daily longacting β2 agonist is more protective than a once-daily... 
Pulmonary/Respiratory | OBSTRUCTIVE PULMONARY-DISEASE | IMPACT | RESPIRATORY SYSTEM | SALMETEROL/FLUTICASONE PROPIONATE | PROPIONATE/SALMETEROL 250/50 | TIOTROPIUM | RISK | PNEUMONIA | TREAT | ROFLUMILAST | SALMETEROL | CRITICAL CARE MEDICINE | Glucocorticoids - administration & dosage | Bronchodilator Agents - administration & dosage | Humans | Middle Aged | Benzyl Alcohols - administration & dosage | Benzyl Alcohols - adverse effects | Male | Pulmonary Disease, Chronic Obstructive - physiopathology | Chlorobenzenes - administration & dosage | Dose-Response Relationship, Drug | Female | Bronchodilator Agents - adverse effects | Glucocorticoids - adverse effects | Pulmonary Disease, Chronic Obstructive - diagnosis | Pneumonia - etiology | Double-Blind Method | Risk Assessment | Pneumonia - epidemiology | Respiratory Function Tests - methods | Administration, Inhalation | Treatment Outcome | Pulmonary Disease, Chronic Obstructive - complications | Disease Progression | Androstadienes - administration & dosage | Chlorobenzenes - adverse effects | Respiratory System - drug effects | Respiratory System - physiopathology | Aged | Drug Monitoring | Androstadienes - adverse effects | Drug Combinations | Pulmonary Disease, Chronic Obstructive - drug therapy
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights